Related Quotes
	Jaguar Health Inc	0.2808	0.0362	11.42%
	Enter Symbols:

Jaguar Health Reports 2023 Financial Results

Net Q4 2023 revenue of approximately $2.3 million decreased 18% versus net Q3 2023 revenue of $2.8 million and decreased approximately 30% versus net Q4 2022 revenue of $3.3 million

Top line results expected forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea

REMINDER: Jaguar to host investor webcast Monday, April 1^st at 8:30 a.m. Eastern regarding Q4 2023 financials and company updates; Click here to register for webcast

SAN FRANCISCO, CA / ACCESSWIRE / April 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2023.

The combined net revenue for Mytesi and the Company's other crofelemer prescription product, Canalevia -CA1, was approximately $9.7 million in the year 2023, representing a decrease of 18% over the combined net revenue in the year 2022, which totaled approximately $11.9 million. The combined net revenue for Mytesi and Canalevia-CA1 was approximately $2.3 million in the fourth quarter of 2023, representing a decrease of 18% over prescription product net revenue in the third quarter of 2023, which totaled approximately $2.8 million, and a decrease of approximately 30% over prescription product net revenue in the fourth quarter of 2022, which totaled approximately $3.3 million.

Lisa Conte, Jaguar's president and CEO, said, "Our paramount near-term clinical activity is our Phase 3 pivotal OnTarget trial of Mytesi for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as unpredictable and/or chronic debilitating diarrhea and GI urgency. Top line results from this pivotal study are forthcoming."

Jaguar is supporting investigator-initiated and IND proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU and Middle East/North Africa (MENA) regions, with results expected in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID for these debilitating conditions.

COMPANY FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023:

• Net Mytesi and Canalevia-CA1 Revenue: The combined net revenue for these two prescription productswas approximately $9.7 million in the year 2023, representing a decrease of approximately 18% over the combined prescription product net revenue in the year 2022, which totaled approximately $11.9 million. The combined prescription net revenue was approximately $2.3 million in the fourth quarter of 2023, representing a decrease of 18% over the combined prescription net revenue in the third quarter of 2023, which totaled approximately $2.8 million, and a decrease of approximately 30% over the combined prescription net revenue in the fourth quarter of 2022, which totaled approximately $3.3 million.
• Mytesi Prescription Volume: Mytesi total prescription volume decreased approximately 4% in the year 2023 over 2022. Mytesi total prescription volume increased slightly by approximately 1% in the fourth quarter of 2023 over the third quarter of 2023 and decreased by approximately 4% in the fourth quarter of 2023 over the fourth quarter of 2022. Prescription volume differs from invoiced sales volume, which reflects, among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels.
• Neonorm : Revenues for the non-prescription Neonorm products were minimal for the fourth quarters of 2023 and 2022, in accordance with the Company's primary focus on human health and prescription products.

• Cost of Product Revenue: Total cost of product revenue remained constant at $2.0 million for the year 2023 and the year 2022.
• Research and Development: The R&D expense increased by $1.0 million, from $17.6 million for the year ended December 31, 2022 compared to $18.6 million in 2023, primarily due to activities related to the OnTarget clinical trial, regulatory activities for the trial, and the company's initiatives for rare disease product development.
• Sales and Marketing: The Sales and Marketing expense decreased by $2.3 million, from $8.8 million in 2022 to $6.5 million in 2023. Direct marketing fees and expenses decreased due to savings associated with the utilization of a more cost-effective patient support services vendor, other Mytesi marketing initiatives, as well as decreased stock-based compensation, and commission expenses.
• General and Administrative: The G&A expense decreased by $1.3 million, from $17.9 million in 2022 to $16.6 million in 2023, mainly due to decreased public company expenses, personnel and related benefits, stock-based compensation and other expenses totaling $2.6 million. However, this decrease is offset by the increase in legal services, lease expenses, audit, tax and accounting services, and travel expenses totaling $1.3 million.
• Loss from Operations: Loss from operations decreased $0.1 million from $34.4 million in 2022 to $34.3 million in 2023 which included an impairment loss on intangible assets of $0.4 million.
• Net Loss: Net loss attributable to common shareholders decreased by approximately $6.2 million in 2023, from $47.5 million in 2022 to $41.3 million in 2023. In addition to the loss from operations:
  • Interest expenses decreased by $6.3 million from $12.7 million in the year ended December 31, 2022 to $6.4 million for the year ended December 31, 2023, primarily due to certain debt instruments being accounted for using the fair value option. The lower interest expense was offset with a higher loss on change in fair value of debt instruments.
  • Change in fair value of financial instrument and hybrid instrument designated at FVO increased by $5.1 million, from $0.02 million in 2022 to $5.1 million in the year 2023, primarily due to fair value adjustments in liability classified warrants and notes payable designated at FVO.
  • Gain on extinguishment of debt increased by $5.9 million, from a loss of $2.2 million in 2022 to a gain of $3.7 million in 2023.
• Non-GAAP Recurring EBITDA: Non-GAAP recurring EBITDA for 2023 and 2022 were a net loss of $34.5 million and $27.4 million, respectively.

Note Regarding Use of Non-GAAP Measures

The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.

The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar's performance and provide useful information to investors regarding the Company's results of operations and financial condition.

Participation Instructions for Webcast

When: Monday, April 1, 2024, at 8:30 AM Eastern Time

Participant Registration & Access Link: Click Here

Replay Instructions for Webcast

Replay of the webcast on the investor relations section of Jaguar's website: (click here)

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/

Visit Jaguar on X: https://twitter.com/Jaguar_Health

Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/

About Mytesi

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Important Safety Information About Canalevia -CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

See full Prescribing Information at Canalevia.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will host an investor webcast on April 1, 2024, the Company's expectation that top line results from the OnTarget study are forthcoming, the Company's expectation that published data from the investigator-initiated and IND proof-of-concept studies that Jaguar is supporting of crofelemer for MVID and SBS with intestinal failure could support reimbursed early patient access to crofelemer for these conditions. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.